Selected Publications
ZMB Publications
Selected Publications
The list provides selected publications of the ZMB from 2004 to 2020, published in the journals listed below.
You can narrow it down by year and author. If an error accured or no data was found, please reload or reset the page.
(View all ZMB publications via the interface of the university bibliography).
Journals
- ACS Nano
- Acta Neuropathologica
- Advanced Drug Delivery Reviews
- All Nature Journals
- American Journal of Human Genetics
- Angewandte Chemie International Edition
- Annals of Oncology
- Annual Review of Biochemistry
- Annual Review of Genetics
- Annual Review of Microbiology
- Biomaterials
- Biotechnology Advances
- Blood
- Brain
- Cancer Cell
- Cancer Discovery
- Cancer Research
- Cell Clinical Cancer Research
- Chemical Reviews
- Chemical Society Reviews
- Circulation
- Circulation Research
- EMBO Molecular Medicine
- EMBO Reports
- Endocrine Reviews
- European Heart Journal
- FEMS Microbiology Reviews
- Gastroenterology
- Gut
- Immunity
- Immunological Reviews
- JAMA: Journal of the American Medical Association
- JAMA Oncology
- JAMA Neurology
- Journal of Hepatology
- Journal of the American Chemical Society
- Journal of the American Medical Association
- Journal of Clinical Oncology
- Journal of Hepatology
- Lancet
- Leukemia
- Molecular Cell
- Molecular Psychiatry
- Natural Product Research
- Nature
- Nature Biotechnology
- Nature Chemical Biology
- Nature Communications
- Nature Genetics
- Nature Medicine
- Nature Methods
- Nature Nanotechnology
- Nature Reviews Molecular Cell Biology
- Nature Reviews Neurology
- Nature Structural & Molecular Biology
- Neuro-Oncology
- Nucleic Acids Research
- Proceedings of the National Academy of Sciences of the United States of America Science
- Science
- Science Advances
- The British Journal of Cancer
- The EMBO Journal
- The Lancet
- The Lancet Diabetes and Endocrinology
- The Lancet Infectious Diseases
- The Lancet Oncology
- The New England Journal of Medicine
- Trends in Pharmacological Sciences
There were 882 publications found
-
Structural basis for the regulation of nucleosome recognition and HDAC activity by histone deacetylase assembliesIn: Science Advances Vol. 7 (2021) Nr. 2, pp. eabd4413
ISSN: 2375-2548Online Full Text: dx.doi.org/ (Open Access) -
Safety and efficacy of prednisone versus placebo in short-term prevention of episodic cluster headache : A multicentre, double-blind, randomised controlled trialIn: The Lancet Neurology Vol. 20 (2021) Nr. 1, pp. 29 - 37
ISSN: 1474-4465; 1474-4422Online Full Text: dx.doi.org/ -
Corrigendum to “Inhibiting fibroblast growth factor receptors in cancer – The next generation”In: Annals of Oncology Vol. 32 (2021) Nr. 1, pp. 126
ISSN: 1569-8041; 0923-7534Online Full Text: dx.doi.org/ (Open Access) -
Non-classical monocyte homing to the gut via α4β7 integrin mediates macrophage-dependent intestinal wound healingIn: Gut Vol. 69 (2020) pp. 252 - 263
ISSN: 1468-3288; 0017-5749Online Full Text: dx.doi.org/ -
Fragile X mental retardation protein protects against tumour necrosis factor-mediated cell death and liver injuryIn: Gut Vol. 69 (2020) Nr. 1, pp. 133 - 145
ISSN: 1468-3288; 0017-5749Online Full Text: dx.doi.org/ (Open Access) -
From dolastatin 13 to cyanopeptolins, micropeptins, and lyngbyastatins : the chemical biology of Ahp-cyclodepsipeptidesIn: Natural Product Reports Vol. 37 (2020) Nr. 2, pp. 163 - 174
ISSN: 0265-0568; 1460-4752Online Full Text: dx.doi.org/ -
Present and Future of Surface-Enhanced Raman ScatteringIn: ACS Nano Vol. 14 (2020) Nr. 1, pp. 28 - 117
ISSN: 1936-086X; 1936-0851Online Full Text: dx.doi.org/ (Open Access) -
Metabolic heterogeneity confers differences in melanoma metastatic potentialIn: Nature Vol. 577 (2020) Nr. 7788, pp. 115 - 120
ISSN: 1476-4687; 0028-0836Online Full Text: dx.doi.org/ Online Full Text (Open Access) -
STAT3 activation through IL-6/IL-11 in cancer-associated fibroblasts promotes colorectal tumour development and correlates with poor prognosisIn: Gut Vol. 69 (2020) Nr. 7, pp. 1269 - 1282
ISSN: 0017-5749Online Full Text: dx.doi.org/ -
Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanomaIn: Annals of Oncology Vol. 31 (2020) Nr. 1, pp. 144 - 152
ISSN: 1569-8041; 0923-7534Online Full Text: dx.doi.org/ -
Molecular subgrouping of primary pineal parenchymal tumors reveals distinct subtypes correlated with clinical parameters and genetic alterationsIn: Acta Neuropathologica Vol. 139 (2020) Nr. 2, pp. 243 - 257
ISSN: 1432-0533; 0001-6322Online Full Text: dx.doi.org/ -
Heterobifunctional Rotaxanes for Asymmetric CatalysisIn: Angewandte Chemie International Edition Vol. 59 (2020) Nr. 13, pp. 5102 - 5107
ISSN: 1521-3773; 1433-7851; 0570-0833Online Full Text: dx.doi.org/ (Open Access) -
Strong suppression of gene conversion with increasing DNA double-strand break load delimited by 53BP1 and RAD52In: Nucleic Acids Research Vol. 48 (2020) Nr. 4, pp. 1905 - 1924
ISSN: 1362-4962; 0305-1048Online Full Text: dx.doi.org/ (Open Access) -
Inhibition of haspin kinase promotes cell-intrinsic and extrinsic antitumor activityIn: Cancer Research Vol. 80 (2020) Nr. 4, pp. 798 - 810
ISSN: 1538-7445; 0008-5472Online Full Text: dx.doi.org/ Online Full Text (Open Access) -
Cemiplimab in locally advanced cutaneous squamous cell carcinoma : results from an open-label, phase 2, single-arm trialIn: The Lancet Oncology Vol. 21 (2020) Nr. 2, pp. 294 - 305
ISSN: 1474-5488; 1470-2045Online Full Text: dx.doi.org/ -
Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAFv⁶⁰⁰ mutation–positive melanoma receiving adjuvant vemurafenibIn: Annals of Oncology Vol. 31 (2020) Nr. 1, pp. 153 - 159
ISSN: 1569-8041; 0923-7534Online Full Text: dx.doi.org/ -
RIBECCA - A phase IIIb, multi-center, open label study for women with estrogen receptor positive locally advanced or metastatic breast cancer treated with ribociclib (LEE011) in combination with letrozole : Results of the third interim analysisIn: Cancer Research Vol. 80 (2020) Nr. 4,
ISSN: 1538-7445; 0008-5472Online Full Text: dx.doi.org/ -
Corrigendum to “Biomolecule-corona formation confers resistance of bacteria to nanoparticle-induced killing: Implications for the design of improved nanoantibiotics” [Biomaterials 192 (2019) 551–559]In: Biomaterials Vol. 263 (2020) pp. 120371
ISSN: 1878-5905; 0142-9612Online Full Text: dx.doi.org/ -
PD-1 Blockade in Anaplastic Thyroid CarcinomaIn: Journal of Clinical Oncology Vol. 38 (2020) Nr. 23, pp. 2620 - 2627
ISSN: 1527-7755Online Full Text: dx.doi.org/ (Open Access) -
CLR01 protects dopaminergic neurons in vitro and in mouse models of Parkinson’s diseaseIn: Nature Communications Vol. 11 (2020) Nr. 1, pp. 4885
ISSN: 2041-1723Online Full Text: dx.doi.org/ (Open Access) -
Tertiary lymphoid structures improve immunotherapy and survival in melanomaIn: Nature Vol. 577 (2020) Nr. 7791, pp. 561 - 565
ISSN: 0028-0836; 1476-4687Online Full Text: dx.doi.org/ -
Prognosis of patients with stage III melanoma according to American joint committee on cancer version 8 : A reassessment on the basis of 3 independent stage III melanoma cohortsIn: Journal of Clinical Oncology Vol. 38 (2020) Nr. 22, pp. 2543 - 2551
ISSN: 1527-7755; 0732-183XOnline Full Text: dx.doi.org/ (Open Access) -
Nusinersen in adults with 5q spinal muscular atrophy : A non-interventional, multicentre, observational cohort studyIn: The Lancet Neurology Vol. 19 (2020) Nr. 4, pp. 317 - 325
ISSN: 1474-4465; 1474-4422Online Full Text: dx.doi.org/ -
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR) : A multicentre, open-label, phase 1 trialIn: The Lancet Oncology Vol. 21 (2020) Nr. 7, pp. 935 - 946
ISSN: 1474-5488; 1470-2045Online Full Text: dx.doi.org/ -
Safety and efficacy of GABAA α5 antagonist S44819 in patients with ischaemic stroke : A multicentre, double-blind, randomised, placebo-controlled trialIn: The Lancet Neurology Vol. 19 (2020) Nr. 3, pp. 226 - 233
ISSN: 1474-4465; 1474-4422Online Full Text: dx.doi.org/ -
Rationale for Immune Checkpoint Inhibitors plus Targeted Therapy in Metastatic Melanoma : A ReviewIn: JAMA Oncology (2020) in press
ISSN: 2374-2445; 2374-2437Online Full Text: dx.doi.org/ -
Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanomaIn: Nature Medicine Vol. 26 (2020) Nr. 7, pp. 1147
ISSN: 1546-170X; 1078-8956Online Full Text: dx.doi.org/ (Open Access) -
Author Correction: Tertiary lymphoid structures improve immunotherapy and survival in melanomaIn: Nature Vol. 580 (2020) Nr. 7801, pp. E1
ISSN: 1476-4687; 0028-0836Online Full Text: dx.doi.org/ -
Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors.In: Journal of Clinical Oncology Vol. 38 (2020) Nr. 15_Suppl., pp. 109
ISSN: 0732-183X; 1527-7755Online Full Text: dx.doi.org/ -
The anti–PD-1 antibody spartalizumab in combination with dabrafenib and trametinib in advanced BRAF V600–mutant melanoma : Efficacy and safety findings from parts 1 and 2 of the Phase III COMBI-i trialIn: Journal of Clinical Oncology Vol. 38 (2020) Nr. 15_Suppl., pp. 10028
ISSN: 0732-183X; 1527-7755Online Full Text: dx.doi.org/ -
Long-term benefit of adjuvant dabrafenib + trametinib (D+T) in patients (pts) with resected stage III BRAF V600–mutant melanoma : Five-year analysis of COMBI-ADIn: Journal of Clinical Oncology Vol. 38 (2020) Nr. 15_Suppl., pp. 10001
ISSN: 0732-183X; 1527-7755Online Full Text: dx.doi.org/ -
Effect of first-line spartalizumab + dabrafenib + trametinib on immunosuppressive features detected in peripheral blood and clinical outcome in patients (pts) with advanced BRAF V600–mutant melanomaIn: Journal of Clinical Oncology Vol. 38 (2020) Nr. 15_Suppl., pp. 10034
ISSN: 0732-183X; 1527-7755Online Full Text: dx.doi.org/ -
Phase I dose-finding study of oral ERK1/2 inhibitor LTT462 in patients (pts) with advanced solid tumors harboring MAPK pathway alterationsIn: Journal of Clinical Oncology Vol. 38 (2020) Nr. 15_Suppl., pp. 3640
ISSN: 0732-183X; 1527-7755Online Full Text: dx.doi.org/ -
Lower-dosing ponatinib in pre-treated GIST : Results of the POETIG phase II trialIn: Journal of Clinical Oncology Vol. 38 (2020) Nr. 15_Suppl., pp. 11536
ISSN: 0732-183X; 1527-7755Online Full Text: dx.doi.org/ -
Quality of life (QoL) and self-reported function with ripretinib in ≥4th-line therapy for patients with gastrointestinal stromal tumors (GIST) : Analyses from INVICTUSIn: Journal of Clinical Oncology Vol. 38 (2020) Nr. 15_Suppl., pp. 11535
ISSN: 0732-183X; 1527-7755Online Full Text: dx.doi.org/ -
Role of adjuvant imatinib dose in radically resected GIST harboring KIT exon 9 mutationsIn: Journal of Clinical Oncology Vol. 38 (2020) Nr. 15_Suppl., pp. 11533
ISSN: 0732-183X; 1527-7755Online Full Text: dx.doi.org/ -
Safety profile of ripretinib, including impact of alopecia, and Palmar-Plantar Erythrodysesthesia Syndrome (PPES) on patient-reported outcomes (PROs), in ≥ fourth-line advanced gastrointestinal stromal tumors (GIST) : Analyses from INVICTUSIn: Journal of Clinical Oncology Vol. 38 (2020) Nr. 15_Suppl., pp. 11539
ISSN: 0732-183X; 1527-7755Online Full Text: dx.doi.org/ -
Three versus one year of adjuvant imatinib for high-risk gastrointestinal stromal tumor (GIST) : Survival analysis of a randomized trial after 10 years of follow-upIn: Journal of Clinical Oncology Vol. 38 (2020) Nr. 15_Suppl., pp. 11503
ISSN: 0732-183X; 1527-7755Online Full Text: dx.doi.org/ -
Phase II study of cemiplimab in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC) : Longer follow-upIn: Journal of Clinical Oncology Vol. 38 (2020) Nr. 15_Suppl.,
ISSN: 0732-183X; 1527-7755Online Full Text: dx.doi.org/ -
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma : safety run-in and biomarker cohorts of COMBI-iIn: Nature Medicine Vol. 26 (2020) Nr. 10, pp. 1557 - 1563
ISSN: 1546-170X; 1078-8956Online Full Text: dx.doi.org/ -
Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma : Results from the randomized part 3 of the phase III COMBI-i trialIn: Annals of Oncology Vol. 31 (2020) Nr. Suppl. 4, pp. S1172
ISSN: 0923-7534Online Full Text: dx.doi.org/ -
Nivolumab (NIVO) monotherapy or combination therapy with ipilimumab (NIVO+IPI) in advanced melanoma patients with brain metastases : Real-world evidence from the German non-interventional study NICOIn: Annals of Oncology Vol. 31 (2020) Nr. Suppl. 4, pp. 746 - S747
ISSN: 0923-7534Online Full Text: dx.doi.org/ -
Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS) : a double-blind, randomised, placebo-controlled, phase 3 trialIn: The Lancet Oncology Vol. 21 (2020) Nr. 7, pp. 923 - 934
ISSN: 1474-5488; 1470-2045Online Full Text: dx.doi.org/ -
Acid ceramidase of macrophages traps herpes simplex virus in multivesicular bodies and protects from severe diseaseIn: Nature Communications Vol. 11 (2020) Nr. 1, pp. 1338
ISSN: 2041-1723Online Full Text: dx.doi.org/ Online Full Text (Open Access) -
Lactate released by inflammatory bone marrow neutrophils induces their mobilization via endothelial GPR81 signalingIn: Nature Communications Vol. 11 (2020) Nr. 1, pp. 3547
ISSN: 2041-1723Online Full Text: dx.doi.org/ (Open Access) -
Structure-based evolution of a promiscuous inhibitor to a selective stabilizer of protein–protein interactionsIn: Nature Communications Vol. 11 (2020) Nr. 1, pp. 3954
ISSN: 2041-1723Online Full Text: dx.doi.org/ (Open Access) -
Inhibiting fibroblast growth factor receptors in cancer – the next generationIn: Annals of Oncology Vol. 31 (2020) Nr. 10, pp. 1285 - 1286
ISSN: 1569-8041; 0923-7534Online Full Text: dx.doi.org/ -
A clinical perspective on the 2019 ESC/EAS guidelines for the management of dyslipidaemias: PCSK-9 inhibitors for all?In: European Heart Journal Vol. 41 (2020) Nr. 24, pp. 2331
ISSN: 1522-9645Online Full Text: dx.doi.org/ -
Role of HLA-DP Expression in Graft-Versus-Host Disease After Unrelated Donor TransplantationIn: Journal of Clinical Oncology Vol. 38 (2020) Nr. 24, pp. 2712 - 2718
ISSN: 1527-7755; 0732-183XOnline Full Text: dx.doi.org/ -
Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide TherapyIn: Gastroenterology Vol. 158 (2020) Nr. 8, pp. 2180 - 2194
ISSN: 1528-0012; 0016-5085Online Full Text: dx.doi.org/